Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: Modulation of proto-oncogene expression

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4359-4370

  Kern, Monika A ^a   Helmbach, Heike ^a   Artuc, Metin ^a   Karmann, Dietmar ^a   Jurgovsky, Klaus ^a   Schadendorf, Dirk ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

AP 1; Chemoresistance; fos; jun; Melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; FOTEMUSTINE; MESSENGER RNA; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN P53; TRANSCRIPTION FACTOR AP 1; VINDESINE;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MELANOMA; MESSENGER RNA SYNTHESIS; MULTIGENE FAMILY; ONCOGENE C JUN; PHENOTYPE; PRIORITY JOURNAL; PROTO ONCOGENE;

EID: 0031426817     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Ahmann DL, Creagan ET, Hahn RG, Edmondson JR, Bisel BF, Schaid DJ: Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 63: 224-227, 1989.
2. Angel P, Karin M: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochem Biophys Acta 1072: 129-157, 1991.
3. Artuc M, Nürnberg W, Czarnetzki BM, Schadendorf D: Characterization of gene regulatory elements for selective gene expression in human melanoma cells. Biochem Biophys Res Comm 213: 699-704, 1995.
4. Baker SJ, Markowitz S, Fearon ER, Willson KV, Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915, 1990.
5. Beck WT, Danks MK: Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Sem Cancer Biol 2: 235-244, 1991.
6. Bergelson S, Pinkus R, Daniel V: Intracellular glutathione levels regulate Fos/Jun induction and activation of glutathione S-transferase. Cancer Res 54: 36-40, 1994.
7. Bhushan A, Abramson R, Chiu JF, Tritton TR: Expression of c-fos in human and murine multidrug-resistant cells. Mol Pharmacol 42: 69-74, 1992.
8. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB: bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608, 1993.
9. Bradley G, Juranka PF, Ling V: Mechanism of multidrug resistance. Biochim Biophys Acta 948: 7-128, 1988.
10. Chaney SG, Sancar A: DNA repair: enzymatic mechanisms and relevance to drug response. J Nat Cancer Inst 88: 1346-1360, 1996.
11. Craig RW: The BCL-2 gene family. Seminars in Cancer Biology 6: 35-43, 1995.
12. Dancey J, Steward WP: The role of vindesine in oncology -recommendations after 10 years' experience. Anti-Cancer Drugs 6: 625-636, 1995.
13. Devary Y, Gottlieb RA, Smeal T, Karin M: The mammalian ultraviolet response is triggered by activation of Src tyrosine kinase. Cell 71: 1081-1091, 1992.
14. Doyle LA, Ross DD, Ordonez JV, Yang W, Gao Y, Tong Y, Belani CP, Gutheil JC: An etoposide-resistant lung cancer subline overexpresses the multidrug resistance associated protein. Br J Cancer 72: 535-542, 1995.
15. Eliopoulos AG, Kerr DJ, Herod J, Hogkins L, Krajewski S, Reed JC, Young LS: The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 11: 1217-1228, 1995.
16. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang W-W, Owen-Schaub LB, Roth JA: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus mediated transfer of the wild-type p53 gene. Cancer Res 54: 2287-2291, 1994.
17. Garbe C: Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 3: 291-299, 1993.
18. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 62: 385-427, 1993.
19. Harris AL, Hochhauser D: Mechanisms of multidrug resistance (MDR) in cancer treatment. Acta Oncol 31: 205-213, 1992.
20. Henwood JM, Brogden RN: Etoposide - a review of its pharmacodynamic and pharmcokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 39: 438-490, 1990.
21. Ho VC, Sober AJ: Therapy of cutaneous melanoma: an update. J Am Acad Dermatol 22: 159-176, 1990.
22. Hollander MC, Fornace AJ: Induction of fos RNA by DNA-damaging agents. Cancer Res 49: 1687-1692, 1989.
23. Hughes P, Dragunow M: Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol Rev 47: 133-178, 1995.
24. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, Namer M, Bonneterre J, Kerbrat P, Bonerandi JJ, Bugat R, Montcuquet P, Cupissol D, Lauvin R, Vilmer C, Prache C, Bizzari JP: Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66: 1873-1878, 1990.
25. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J: bcl-2 protein inhibits etoposide-induced apoptosis through ist effect on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 53: 4251-4256, 1993.
26. Kim R, Beck WT: Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26. Cancer Res 54: 4958-4966, 1994.
27. Lee YJ, Galoforo SS, Berns CM, Erdos G, Gupta AK, Ways DK, Corry PM: Effect of ionizing radiation on AP-1 binding activity and basic fibroblast growth factor gene expression in drug-sensitive human breast carcinoma MCF-7 and multidrug-resistant MCF-7/ADR cells. J Biol Chem 270: 28790-28796, 1995.
28. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
29. Lowry OH, Rosebrough NJ, Farr AL, Randall AJ: Protein measurement with folin phenol reagent. J Biol Chem 193: 265-275, 1951.
30. Moffat GJ, McLaren AW, Wolf CR: Involvment of Jun and Fos proteins in regulating transcriptional activation of the human Pi class glutathione S-transferase gene in multidrug-resistant MCF7 breast cancer cells. J Biol Chem 269: 16397-16402, 1994.
31. Nooter K, Herweijer H: Multidrug resistance (mdr) genes in human cancer. Brit J Cancer 63: 663-669, 1991.
32. Nurnberg W, Artuc M, Vorbrueggen G, Kalkbrenner F, Molling K, Czametzki BM, Schadendorf D: Nuclear proto-oncogenes transactivate the HPV-16 promotor. Brit J Cancer 71: 1018-1024, 1995.
33. Oltvai Z N, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
34. Rubin E, Kharbanda S, Gunji H, Kufe D: Activation of the c-jun proto-oncogene in human myeloid leukemia cells treated with etoposide. Mol Pharmacol 39: 697-701, 1991.
35. Rubin E, Kharbanda S, Gunji R, Weichselbaum R, Kufe D: cis diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway. Cancer Res 52: 878-882, 1992.
36. Sambrook J, Fritsch EF, Maniatis T: Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory Press Cold Spring Harbor New York, 1989.
37. Scanlon KJ, Ishida H, Kashani-Sabet M: Ribozyme-mediated reversal of the multidrug resistant phenotype. Proc Natl Acad Sci USA 91: 11123-11127, 1994.
38. Scanlon KJ, Jiao L, Funato T, Wang W, Tone T, Rossi JJ, Kashani-Sabet M: Ribozyme mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA 88: 10591-10595, 1991.
39. Schadendorf D, Worm M, Algermissen B, Kohlmus CM, Czarnetzki BM: Chemosensitivity testing of human melanoma cells -retrospective analysis of clinical response and in vitro drug sensitivity. Cancer 73: 103-108, 1994.
40. Schadendorf D, Jurgovsky K, Worm M, Czarnetzki BM: Sensitivity of human melanoma cells in vitro to chemotherapy, interferons and combinations of both. Melanoma Res 4: 423-429, 1994.
41. Schadendorf D, Makki A, Stahr C, Van Dyck A, Wanner R, Scheffer GL, Flens MJ, Scheper R, Henz BM: Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol 147: 1545-1552, 1995.
42. Smith ML, Fornace AJ Jr: Genomic instability and the role of p53 mutations in cancer cells. Curr Opin Oncol 7: 69-75, 1995.
43. Versantvoort CHM, Broxterman HJ, Bagrij T, Scheper RJ, Twentyman PR: Regulation by glutathione of drug-transport in multidrug-resistant human lung tumor cell lines overexpressing multidrug resistance-associated protein. Br J Cancer 72: 82-89, 1995a.
44. Versantvoort CHM, Withoff S, Broxterman HJ, Kuiper CM, Scheper RJ, Mulder NH, de Vries EGE: Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance. Int J Cancer 61: 375-380, 1995b.
45. Volm M: P-glycoprotein associated expression of c-fos and c-jun products in human lung carcinomas. Anticancer Res 13: 375-378, 1993.
46. Walton MI, Whysong D, O Connor PM, Hockenbery D, Korsmeyer SJ, Kohn KW: Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 53: 1853-1861, 1993
47. Yamada M, Tomida A, Yoshikawa H, Taketani Y, Tsuruo T: Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines. Clin Cancer Res 2: 427-432, 1996.
48. Yao K-S, Godwin A K, Johnson SW, Ozols RF, O Dwyer PJ, Hamilton TC: Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 55: 4367-4374, 1995.
49. Yokomizo A, Ono M, Nanri H, Makino Y, Ohga T, Wada M, Okamoto T, Yodoi J, Kuwano M, Kohno, K. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 55: 4293-4296, 1995.
50. Yu L, Cohen D, Piekarz RL, Horwitz SB: Three distinct nuclear protein binding sites in the promoter of the murine multidrug resistance mdrlb gene. J Biol Chem 268: 7520-7526, 1993.
51. Zhao R, Rabo YB, Egyhazi S, Andersson A, Edgren MR, Lindner S, Hansson J: Apoptosis and c-jun induction by cisplatin in a human melanoma cell line and a drug-resistant daughter cell line. Anti-Cancer Drugs 6: 657-668, 1995.